Anesthesia clinicians reason about hypotension causally at the bedside — vasodilation, hypovolemia, myocardial depression, bradycardia — and intervene accordingly. The case-level reasoning is sound. The dataset-level pattern across hundreds of events is invisible. M&M handles individual cases; PSI-90 reports the composite score; neither tells you what was driving your group’s IOH events last quarter. LINCR runs that audit on case data your AIMS already produces.
Per-quarter cause distribution across every IOH event in your group’s case data, segmented by case type, length, anesthetic technique, and patient profile. Example finding: “63% of last quarter’s IOH events were vasodilation-mediated, clustered in cases longer than three hours with high MAC and propofol infusion.”
Case-mix-normalized IOH burden per anesthesiologist, with cause distribution and example cases attached for medical-director review. Example finding: “Dr. Smith’s vasodilation-mediated IOH burden is 2.4× group median, clustering in laparoscopic cases on high propofol infusion. 12 representative cases attached.”
Audit reports your QI committee, hospital quality department, and malpractice carrier can point to as evidence of structured QI activity. Documents that the group identified, attributed, and acted on a pattern.
Live demo running the audit against the MOVER dataset (UC Irvine, 55,483 anesthesia cases, JAMIA Open 2023). One representative case with five IOH events spanning four different cause attributions, plus the aggregate distribution across 300 randomly sampled cases.
The audit is powered by CF2, a 63,975-parameter neural-ODE model that estimates per-subject physiological state from observable signals (blood pressure waveform or NIBP cuff, ECG, pulse oximetry, capnography, drug record). Validated against MOVER, VitalDB, MIMIC-IV, and eICU with publication-grade calibration on hypotension prediction. US provisional patent filed 2026-03-20 (USPTO #64/011,899, sole inventor: Anish Joseph).
Today’s product is the retrospective audit and the prospective risk-stratifier that follows in months three through six. Both ship under the FD&C Act §520(o)(1)(E) clinical-decision-support carve-out (21st Century Cures), so deployment does not require 510(k) clearance. Real-time bedside CDS is the year-two-to-three roadmap and will go through 510(k); not claimed as available now.
I administer the vasopressors, fluids, and inotropes the audit reasons about — on the patients in the populations the model is trained on. The model is mine (sole inventor on the provisional patent). The product is built around what an anesthesiologist actually classifies at the bedside, not around what an analytics layer can detect post hoc. Clinical questions welcome on the call.
If your group has IOH events that the current quality reporting doesn’t fully explain, this is worth one phone call. The 90-day audit is at no cost during the pilot phase and the audit findings are yours regardless of whether we proceed to a contract.
Email anish@lincr.io